JP Morgan Chase’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-605,742
| Closed | -$12.9M | – | 7846 |
|
|
2024
Q1 | $12.9M | Buy |
605,742
+591,709
| +4,217% | +$7.08M | ﹤0.01% | 2255 |
|
|
2023
Q4 | $135K | Buy |
14,033
+14,031
| +701,550% | +$68.2K | ﹤0.01% | 5598 |
|
|
2023
Q3 | $5 | Hold |
2
| – | – | ﹤0.01% | 7365 |
|
|
2023
Q2 | $9 | Hold |
2
| – | – | ﹤0.01% | 6822 |
|
|
2023
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7349 |
|
|
2022
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 7125 |
|
|
2022
Q3 | $0 | Sell |
2
-4,350
| -100% | -$10.9K | ﹤0.01% | 6967 |
|
|
2022
Q2 | $11K | Hold |
4,352
| – | – | ﹤0.01% | 6020 |
|
|
2022
Q1 | $34K | Hold |
4,352
| – | – | ﹤0.01% | 5929 |
|
|
2021
Q4 | $18K | Buy |
4,352
+1,361
| +46% | +$8.49K | ﹤0.01% | 6247 |
|
|
2021
Q3 | $24K | Buy |
2,991
+948
| +46% | +$7.98K | ﹤0.01% | 6012 |
|
|
2021
Q2 | $17K | Buy |
2,043
+2,019
| +8,413% | +$17.4K | ﹤0.01% | 5959 |
|
|
2021
Q1 | $0 | Hold |
24
| – | – | ﹤0.01% | 6436 |
|
|
2020
Q4 | $0 | Buy |
+24
| New | +$301 | ﹤0.01% | 6011 |
|
JP Morgan Chase's FUSN Position: Q2 2024 in Review
JP Morgan Chase sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 605,742 shares — an estimated $12.9M sold.
JP Morgan Chase first reported a position in FUSN in Q4 2020 and held it in 14 quarters. The position peaked at $12.9M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- JP Morgan Chase reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 605,742 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $12.9M.
- JP Morgan Chase first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 14 quarters.
- JP Morgan Chase's Fusion Pharmaceuticals Inc. Common Shares position peaked at $12.9M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.